Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
275 studies found for:    "Breast Neoplasms, Male"
Show Display Options
Rank Status Study
21 Completed Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
22 Completed Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: gefitinib;   Other: laboratory biomarker analysis
23 Completed Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: bevacizumab;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis
24 Withdrawn Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Drug: cyclophosphamide;   Biological: ex vivo-expanded HER2-specific T cells;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunoenzyme technique
25 Active, not recruiting FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
Conditions: Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Device: positron emission tomography;   Device: dynamic contrast-enhanced magnetic resonance imaging;   Other: laboratory biomarker analysis
26 Active, not recruiting
Has Results
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: adenovirus-p53 transduced dendritic cell (DC) vaccine;   Drug: 1-methyl-d-tryptophan;   Other: Laboratory biomarker analysis
27 Completed
Has Results
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Drug: paclitaxel;   Biological: bevacizumab
28 Completed
Has Results
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
Conditions: Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: bevacizumab;   Drug: paclitaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Radiation: radiation therapy;   Drug: tamoxifen citrate;   Drug: aromatase inhibition therapy
29 Completed Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: becatecarin;   Other: laboratory biomarker analysis
30 Terminated Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
31 Active, not recruiting Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Procedure: leukapheresis;   Biological: ex vivo-expanded HER2-specific T cells;   Drug: cyclophosphamide;   Biological: sargramostim;   Other: laboratory biomarker analysis
32 Completed Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: trastuzumab
33 Completed
Has Results
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: ixabepilone;   Drug: carboplatin;   Other: laboratory biomarker analysis
34 Terminated Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: alvocidib;   Other: laboratory biomarker analysis;   Other: pharmacological study
35 Completed Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: pharmacological study
36 Terminated Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
37 Terminated
Has Results
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Conditions: Male Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: oblimersen sodium;   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
38 Completed Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: paclitaxel;   Biological: bavituximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
39 Active, not recruiting Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Procedure: leukapheresis;   Other: laboratory biomarker analysis;   Biological: sargramostim;   Other: immunologic technique;   Biological: synthetic tumor-associated peptide vaccine therapy
40 Active, not recruiting Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions: Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.